Sign in
Taking peopleNo phase

Inulin and methylcellulose fibre supplements for irritable bowel syndrome, compared with placebo

Tests how well inulin with methylcellulose is tolerated and affects gas in irritable bowel syndrome.

Key facts

Who runs it
University of Nottingham
Where
United Kingdom2 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Effect of Chronic Feeding of Inulin And Methylcellulose on Colonic Fermentation
Status
Recruiting
People taking part
35 people, planned
Started
30 Sept 2024
Planned end
30 Jun 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • methylcellulose
  • inulin
  • maltodextrin
Record updated
15 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with no or only mild gut symptoms. It tests how well people tolerate fibre (inulin with methylcellulose or with placebo) and how much gas it makes.

Age
18 to 65 years
Sex
All sexes
Disease stage
Score of 5 or less (mild or less) for wind, bloating, belly pain, loose stool and hard stool in the previous 2 weeks.
Earlier treatment
People who cannot stop drugs that change gut movement (such as mebeverine, opiates, benzodiazepines) cannot join. People taking antibiotics or probiotics cannot join.

Main reasons for not taking part

  • Pregnant, breastfeeding or planning pregnancy
  • Existing gut disorder that may affect bowel function, or past surgery removing part of the gullet, stomach or bowel (appendix excepted), or a stoma
  • Diabetes, lung disease limiting use of the breath test, or known intolerance to a test substance
  • BMI less than 18.5 or greater than 35
  • Night shift work in the week before the study day, or a research study with invasive procedures in the last 3 months

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • • Aged between 18 and 65 years old; Able to give informed consent; Scoring ≤5 (i.e., mild, or less) for symptoms of flatulence, bloating, abdominal pain, loose stool, and hard stool in previous 2 weeks using a modified Gastrointestinal Symptom Rating Scale (5); Agrees to consume the meals provided; Agrees to not smoke during the breath hydrogen sampling period

Who cannot take part

  • • Pregnancy, lactating, or planning pregnancy during the course of the investigation declared by candidate; History declared by the candidate of pre-existing gastrointestinal disorder that may affect bowel function; Reported history of previous resection of the oesophagus, stomach, or intestine (excluding appendix); Intestinal stoma; Any medical condition making participation potentially compromising participation in the study e.g., diabetes mellitus, respiratory disease limiting ability to use breath hydrogen analyser, known intolerance to one of the test substances; Has a body mass index (BMI) value less than 18.5 or greater than 35; Will not agree to follow dietary and lifestyle restrictions required; Unable to stop drugs known to alter GI motility including mebeverine, opiates, monoamine oxidase inhibitors, phenothiazines, benzodiazepines, calcium channel antagonists for the duration of the study (Selective serotonin reuptake inhibitors, low dose tricyclic antidepressants, antihistamines, and oral contraceptive pill will be recorded in the CRF but will not be an exclusion criteria); Participants who are taking antibiotics or probiotics as it might alters gut microbiota; Poor understanding of English language; Participation in night shift work the week prior to the study day. Night work is defined as working between midnight and 6.00 AM; Anyone who in the opinion of the investigator is unlikely to be able to comply with the protocol e.g., cognitive dysfunction, chaotic lifestyle related to substance abuse; Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To determine the effect on tolerance and gas production from chronic feeding of fermentable fibre (inulin) incorporated into a gel forming fibre (methylcellulose) compared with placebo (maltodextrin)

The 2 groups in the trial

  • methylcelluloseExisting treatment, for comparison

    2.5 g of Inulin and 2.5g methylcellulose in 62.5 mL water given thrice daily for 7 days increasing to 5 g of Inulin and 5g methylcellulose in 125 mL water on day 8 continuing until day 14

    Treatment: methylcellulose and inulin

  • PlaceboPlacebo, for comparison

    2.5 g of Inulin and 2.5g maltodextrin in 62.5 mL water given thrice daily for 7 days increasing to 5 g of Inulin and 5g maltodextrin in 125 mL water on day 8 continuing until day 14

    Treatment: inulin and maltodextrin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Randomised Placebo Controlled Trial of Chronic Feeding of INuliN And Methylcellulose On Colonic fermentatioN
Plain-language title
Inulin and methylcellulose fibre supplements for irritable bowel syndrome, compared with placeboGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06551961, who can take part
Record updated
15 November 2024